INVESTOR ALERT: Glancy Binkow & Goldberg LLP Announces an Expanded Class Period in the Shareholder Lawsuit Against Aeterna Ze...
January 06 2015 - 7:18PM
Business Wire
Glancy Binkow & Goldberg LLP announces that a class action
complaint has been filed with an expanded Class Period in the
shareholder lawsuit pending in the United States District Court for
the District of New Jersey against Aeterna Zentaris Inc. (“Aeterna”
or the “Company”) (NASDAQ:AEZS). The complaint alleges violations
of federal securities laws and asserts claims on behalf of
purchasers of Aeterna securities between April 2, 2012 and November
6, 2014, inclusive (the “Class Period”).
Aeterna is a specialty biopharmaceutical company engaged in the
development and commercialization of novel treatments in oncology
and endocrinology. The Company is developing macimorelin − an
orally active small molecule that stimulates the secretion of
growth hormone − as a treatment for Adult Growth Hormone
Deficiency. The lawsuit alleges that defendants misrepresented or
failed to disclose that: (1) the planned analysis of macimorelin’s
pivotal clinical trial failed to meet its primary efficacy endpoint
pursuant to the Special Protocol Assessment agreement letter
between the Company and the FDA; (2) insufficient data existed to
confirm that the patients in the clinical trial were accurately
diagnosed with Adult Growth Hormone Deficiency; (3) a serious
cardiac event could have been attributed to macimorelin; (4) as a
result, the FDA would not approve the New Drug Application for
macimorelin in its present form; and (5), the Company’s statements
about its business, operations and prospects, including statements
about macimorelin’s prospects for FDA approval, were materially
false and misleading and/or lacked a reasonable basis.
If you purchased Aeterna securities between April 2, 2012 and
November 6, 2014, you may move the Court no later than January 12,
2015, to serve as lead plaintiff, if you meet certain legal
requirements. To be a member of the Class you need not take any
action at this time; you may retain counsel of your choice or take
no action and remain an absent member of the Class. If you wish to
learn more about this action, or have any questions concerning this
announcement or your rights or interests with respect to these
matters, please contact Casey Sadler, Esquire, of Glancy Binkow
& Goldberg LLP, 1925 Century Park East, Suite 2100, Los
Angeles, California 90067, Toll-Free at 888-773-9224, by e-mail to
shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los AngelesCasey Sadler,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024